About Putative divalent cation/proton antiporter TMEM165
Putative divalent cation/proton antiporter TMEM165 (TMEM165) is a protein
from Homo sapiens identified by UniProt accession
Q9HC07, 324 residues long.
MolForge cross-references it against 0 known binders and
161 disease associations.
Target properties
| Protein name | Putative divalent cation/proton antiporter TMEM165 |
| UniProt accession | Q9HC07 |
| Gene | TMEM165 |
| Organism | Homo sapiens |
| Length | 324 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (161)
Diseases linked to this target (Open Targets).
- TMEM165-congenital disorder of glycosylation · score 0.80
- congenital disorder of glycosylation · score 0.51
- body fat percentage · score 0.30
- fat body mass · score 0.23
- systolic blood pressure · score 0.18
- metabolite measurement · score 0.17
- C-reactive protein measurement · score 0.16
- hip circumference · score 0.15
- IGF-1 measurement · score 0.14
- waist-hip ratio · score 0.13
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9HC07-F1 | alphafold | PREDICTED | 76.21 | — |
Amino-acid sequence (324 residues)
MAAAAPGNGR ASAPRLLLLF LVPLLWAPAA VRAGPDEDLS HRNKEPPAPA QQLQPQPVAV QGPEPARVEK IFTPAAPVHT NKEDPATQTN LGFIHAFVAA ISVIIVSELG DKTFFIAAIM AMRYNRLTVL AGAMLALGLM TCLSVLFGYA TTVIPRVYTY YVSTVLFAIF GIRMLREGLK MSPDEGQEEL EEVQAELKKK DEEFQRTKLL NGPGDVETGT SITVPQKKWL HFISPIFVQA LTLTFLAEWG DRSQLTTIVL AAREDPYGVA VGGTVGHCLC TGLAVIGGRM IAQKISVRTV TIIGGIVFLA FAFSALFISP DSGF
Explore Putative divalent cation/proton antiporter TMEM165 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets